AI-based algorithm can diagnose heart attacks with better accuracy and speed
UK: An algorithm developed using artificial intelligence (AI) could diagnose heart attacks with better accuracy and speed than ever before, a new study published in Nature Medicine has revealed.
In the new research from the University of Edinburgh, the researchers tested the effectiveness of the algorithm, named CoDE-ACS [2], on 10,286 patients in six countries around the world. They found that compared to current testing methods, CoDE-ACS could rule out a heart attack in more than double the number of patients, with an accuracy of 99.6 per cent.
This ability to rule out a heart attack faster than ever could greatly reduce hospital admissions. Clinical trials are now underway in Scotland, with support from the Wellcome Leap, to assess whether the tool can help doctors reduce pressure on our overcrowded Emergency Departments.
As well as quickly ruling out heart attacks in patients, CoDE-ACS could also help doctors to identify those whose abnormal troponin levels were due to a heart attack rather than another condition. The AI tool performed well regardless of age, sex, or pre-existing health conditions, showing its potential for reducing misdiagnosis and inequalities across the population.
CoDE-ACS has the potential to make emergency care more efficient and effective by rapidly identifying patients that are safe to go home and by highlighting to doctors all who need to stay in the hospital for further tests.
The current gold standard for diagnosing a heart attack is measuring levels of the protein troponin in the blood. But the same threshold is used for every patient. This means that factors like age, sex and other health problems which affect troponin levels are not considered, affecting how accurate heart attack diagnoses are.
This can lead to inequalities in diagnosis. For example, previous BHF-funded research has shown that women are 50 per cent more likely to get a wrong initial diagnosis. Initially misdiagnosed people have a 70 per cent higher risk of dying after 30 days [3]. The new algorithm is an opportunity to prevent this.
CoDE-ACS was developed using data from 10,038 patients in Scotland who had arrived at the hospital with a suspected heart attack. It uses routinely collected patient information, such as age, sex, ECG findings, medical history, and troponin levels, to predict the probability that an individual has had a heart attack. The result is a probability score from 0 to 100 for each patient.
Professor Nicholas Mills, BHF Professor of Cardiology at the Centre for Cardiovascular Science, University of Edinburgh, who led the research, said:
“Early diagnosis and treatment save lives for patients with acute chest pain due to a heart attack. Unfortunately, many conditions cause these common symptoms, and the diagnosis is not always straightforward. Harnessing data and artificial intelligence to support clinical decisions has enormous potential to improve patient care and efficiency in our busy Emergency Departments.”
Professor Sir Nilesh Samani, Medical Director of the British Heart Foundation, said:
“Chest pain is one of the most common reasons people present to Emergency Departments. Every day, doctors worldwide face the challenge of separating patients whose pain is due to a heart attack from those whose pain is due to something less serious.
“CoDE-ACS, developed using cutting-edge data science and AI, has the potential to rule in or rule out a heart attack more accurately than current approaches. It could be transformational for Emergency Departments, shortening the time needed to diagnose, and much better for patients.”
Reference:
Doudesis, D., Lee, K.K., Boeddinghaus, J. et al. Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations. Nat Med (2023). https://doi.org/10.1038/s41591-023-02325-4
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd